Fractyl Health, Inc. Common Stock (GUTS) - Total Liabilities
Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has total liabilities worth $83.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Fractyl Health, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Fractyl Health, Inc. Common Stock - Total Liabilities Trend (2019–2025)
This chart illustrates how Fractyl Health, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Fractyl Health, Inc. Common Stock.
Fractyl Health, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PannErgy Nyrt.
F:PPL
|
Germany | €15.22 Billion |
|
Royce Global Value Trust Inc
NYSE:RGT
|
USA | $432.94K |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
Turkey | TL1.41 Billion |
|
Tong Herr Resources Bhd
KLSE:5010
|
Malaysia | RM121.89 Million |
|
Tat Gida Sanayi AS
IS:TATGD
|
Turkey | TL4.72 Billion |
|
GENOR BIOPHARMA DL-00002
F:67N0
|
Germany | €226.09 Million |
|
Freetrailer Group A/S
ST:FREETR
|
Denmark | Dkr87.41 Million |
|
CAB Cakaran Corporation Bhd
KLSE:7174
|
Malaysia | RM897.72 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Fractyl Health, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Fractyl Health, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -50.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fractyl Health, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fractyl Health, Inc. Common Stock (2019–2025)
The table below shows the annual total liabilities of Fractyl Health, Inc. Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $111.94 Million | +40.54% |
| 2024-09-30 | $79.65 Million | -80.15% |
| 2023-09-30 | $401.27 Million | +28.09% |
| 2022-09-30 | $313.27 Million | +0.45% |
| 2021-09-30 | $311.87 Million | +1474.40% |
| 2020-09-30 | $19.81 Million | -87.05% |
| 2019-09-30 | $152.93 Million | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a nove… Read more